Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY

v3.24.1.1.u2
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($)
Total
Private Placement
Equity Line Of Credit
Preferred Stock
Common Stock
Common Stock
Private Placement
Common Stock
Equity Line Of Credit
Additional Paid-In Capital
Additional Paid-In Capital
Private Placement
Additional Paid-In Capital
Equity Line Of Credit
Accumulated Deficit
Accumulated Other Comprehensive Loss
Balance (in shares) at Dec. 31, 2022       7 1,796,472              
Balance at Dec. 31, 2022 $ 11,407,600     $ 0 $ 17,986     $ 146,035,314     $ (134,462,959) $ (182,741)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Stock-Based Compensation 135,941             135,941        
Issuance of common stock (in shares)           52,798 20,000          
Issuance of Common Stock   $ 115,715 $ 98,960     $ 528 $ 200   $ 115,187 $ 98,760    
Issuance of Common Stock from Warrant Exercises (in shares)         50,000              
Issuance of Common Stock from Warrant Exercises 298,500       $ 500     298,000        
Foreign Currency Translation Adjustment (32,671)                     (32,671)
Net Income (Loss) (1,868,536)                   (1,868,536)  
Balance (in shares) at Mar. 31, 2023       7 1,919,270              
Balance at Mar. 31, 2023 10,155,509     $ 0 $ 19,214     146,683,202     (136,331,495) (215,412)
Balance (in shares) at Dec. 31, 2023       427 7,705,640              
Balance at Dec. 31, 2023 6,109,654     $ 4 $ 77,078     153,192,228     (146,976,855) (182,801)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Stock-Based Compensation 175,443             175,443        
Issuance of common stock (in shares)         15,800,000              
Issuance of Common Stock 13,808,815       $ 158,000     13,650,815        
Issuance of Common Stock from Warrant Exercises (in shares)         2,750,557              
Issuance of Common Stock from Warrant Exercises 1,438,817       $ 27,506     1,411,311        
Foreign Currency Translation Adjustment (81,573)                     (81,573)
Net Income (Loss) 13,453,207                   13,453,207  
Balance (in shares) at Mar. 31, 2024       427 26,256,197              
Balance at Mar. 31, 2024 $ 34,904,363     $ 4 $ 262,584     $ 168,429,797     $ (133,523,648) $ (264,374)